Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Status Recruiting

Clinical Trial Summary

This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in Acute Myeloid Leukemia Minimal Residual Disease(AML MRD). This clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-020a in patients with AML MRD, where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05601830
Study type	Interventional
Source	Institute of Hematology & Blood Diseases Hospital
Contact	Jianxiang Wang
Phone	022-23909120
Email	wangjx@ihcams.ac.cn
Status	Recruiting
Phase	Phase 1
Start date	October 28, 2022
Completion date	October 21, 2025

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04044560` - Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant	Phase 2
Recruiting	`NCT05959720` - Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
Recruiting	`NCT03665480` - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML	Phase 2/Phase 3
Active, not recruiting	`NCT02458014` - Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease	Phase 2
Active, not recruiting	`NCT03233854` - CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies	Phase 1
Active, not recruiting	`NCT04853017` - A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors	Phase 1
Not yet recruiting	`NCT06358430` - Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)	Phase 1
Not yet recruiting	`NCT05603156` - A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive	N/A
Withdrawn	`NCT03699384` - Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)	Phase 1/Phase 2
Recruiting	`NCT06066905` - A Study of Chidamide With AZA in MRD Positive AML After Transplant	N/A
Terminated	`NCT03272633` - Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies	Early Phase 1
Recruiting	`NCT03241940` - Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies	Phase 1
Completed	`NCT03096782` - Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma	Phase 2
Completed	`NCT05093192` - Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia	N/A
Recruiting	`NCT06230185` - ctDNA Based MRD Testing for NAC Monitoring in TNBC
Recruiting	`NCT02400970` - Contamination of Testicle Tissue by RT-PCR in Participants With Solid Tumors	N/A
Recruiting	`NCT02400827` - Contamination of Ovarian Tissue by RT-PCR in Participants With Solid Tumors	N/A
Active, not recruiting	`NCT01894477` - Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia	Phase 2
Active, not recruiting	`NCT04920188` - Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)
Completed	`NCT02714790` - Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia	N/A